Flt1 (Fms related receptor tyrosine kinase 1) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Flt1 (Fms related receptor tyrosine kinase 1) Rattus norvegicus
Symbol: Flt1
Name: Fms related receptor tyrosine kinase 1
RGD ID: 2621
Description: Enables ATP binding activity; growth factor binding activity; and vascular endothelial growth factor receptor activity. Involved in several processes, including liver regeneration; negative regulation of vascular endothelial growth factor production; and positive regulation of cell population proliferation. Located in extracellular space. Used to study corneal neovascularization. Biomarker of breast cancer; liver cirrhosis; myocardial infarction; retinal disease (multiple); and vascular dementia. Human ortholog(s) of this gene implicated in Kuhnt-Junius degeneration; bronchopulmonary dysplasia; diabetic retinopathy; and pre-eclampsia. Orthologous to human FLT1 (fms related receptor tyrosine kinase 1); PARTICIPATES IN vascular endothelial growth factor signaling pathway; axitinib pharmacodynamics pathway; bevacizumab pharmacodynamics pathway; INTERACTS WITH 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine; 2,3,7,8-Tetrachlorodibenzofuran.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: FLT-1; FMS-like tyrosine kinase 1; FMS-related tyrosine kinase 1; Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); LOC100911280; tyrosine-protein kinase receptor FLT; vascular endothelial growth factor receptor 1; vascular endothelial growth factor receptor 1-like; vascular endothelial growth factor/vascular permeability factor receptor; VEGFR-1
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Candidate Gene For: Cia12
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2127,296,899 - 7,468,626 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl127,297,292 - 7,468,626 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx127,981,040 - 8,154,378 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0128,604,183 - 8,777,515 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0127,632,184 - 7,805,529 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0129,033,993 - 9,205,886 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl129,034,308 - 9,205,905 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01210,927,827 - 10,959,880 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4127,858,092 - 8,035,966 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera129,039,046 - 9,210,055 (+)NCBICelera
RH 3.4 Map12 RGD
Cytogenetic Map12p11NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
Acute Lung Injury  (IMP)
allergic contact dermatitis  (ISO)
angiosarcoma  (ISO)
arteriovenous malformations of the brain  (ISO)
atrial fibrillation  (ISO)
autism spectrum disorder  (ISO)
background diabetic retinopathy  (ISO)
breast cancer  (IEP)
Breast Neoplasms  (ISO)
bronchopulmonary dysplasia  (ISO)
cerebral cavernous malformation  (ISO)
Cerebral Hemorrhage  (IEP,ISO)
Chemical and Drug Induced Liver Injury  (ISO)
Choroidal Neovascularization  (IMP,ISO)
chronic obstructive pulmonary disease  (ISO)
colon carcinoma  (ISO)
corneal neovascularization  (IMP)
Coronary Disease  (ISO)
Diabetic Nephropathies  (ISO)
diabetic retinopathy  (IEP,ISO)
Disease Progression  (ISO)
ductal carcinoma in situ  (ISO)
Endometrial Neoplasms  (ISO)
Experimental Arthritis  (ISO)
Experimental Autoimmune Encephalomyelitis  (ISO)
Experimental Diabetes Mellitus  (IEP,ISO)
genetic disease  (ISO)
hydrophthalmos  (ISO)
ischemia  (ISO)
Kawasaki disease  (ISO)
Kidney Neoplasms  (ISO)
Kuhnt-Junius degeneration  (ISO)
leiomyosarcoma  (ISO)
Leydig cell tumor  (ISO)
liver cirrhosis  (IEP,ISO)
lung adenocarcinoma  (ISO)
macular degeneration  (ISO)
macular retinal edema  (ISO)
melanoma  (ISO)
Mycoplasma pneumoniae pneumonia  (ISO)
myocardial infarction  (IEP)
nasopharynx carcinoma  (ISO)
Neointima  (IEP,IMP)
Neoplasm Metastasis  (ISO)
nephroblastoma  (ISO)
osteoarthritis  (ISO)
Osteoarthritis, Experimental  (ISO)
osteochondrodysplasia  (ISO)
Otitis Media with Effusion  (IEP)
Ovarian Neoplasms  (ISO)
pre-eclampsia  (ISO)
proliferative diabetic retinopathy  (ISO)
prostate carcinoma in situ  (ISO)
Prostatic Neoplasms  (ISO)
psoriasis  (ISO)
Recurrence  (ISO)
renal cell carcinoma  (ISO)
retinopathy of prematurity  (IEP,ISO)
Sepsis  (ISO)
Skin Neoplasms  (ISO)
Spinal Cord Injuries  (IEP)
squamous cell carcinoma  (ISO)
thyroid gland carcinoma  (ISO)
transient cerebral ischemia  (ISO)
type 2 diabetes mellitus  (ISO)
uremia  (ISO)
Uterine Cervical Neoplasms  (ISO)
Uterine Neoplasms  (ISO)
vascular dementia  (IEP)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-demecolcine  (ISO)
(R)-lipoic acid  (ISO)
1,1-dichloroethene  (ISO)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',5,5'-tetrachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3,7,8-Tetrachlorodibenzofuran  (EXP)
2,4,6-tribromophenol  (ISO)
2-butoxyethanol  (ISO)
2-hydroxypropanoic acid  (ISO)
3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP)
3,3',4,4',5-pentachlorobiphenyl  (EXP)
3,3',5,5'-tetrabromobisphenol A  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxyphenyl retinamide  (ISO)
5-fluorouracil  (ISO)
5-Hydroxycapric acid  (ISO)
6-propyl-2-thiouracil  (EXP)
[6]-Shogaol  (ISO)
Actein  (EXP)
afimoxifene  (ISO)
aflatoxin B1  (ISO)
Aflatoxin B2 alpha  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
allethrin  (EXP)
aluminium oxide  (ISO)
amitrole  (EXP)
ammonium chloride  (EXP)
andrographolide  (ISO)
arotinoid acid  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
belinostat  (ISO)
benzatropine  (ISO)
benzo[a]pyrene  (ISO)
benzo[e]pyrene  (ISO)
bilirubin IXalpha  (ISO)
biphenyl-2-ol  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bromochloroacetic acid  (ISO)
C60 fullerene  (EXP)
cadmium atom  (ISO)
calcitriol  (ISO)
calcium silicate  (ISO)
cannabidiol  (ISO)
carbon nanotube  (ISO)
CGP 52608  (ISO)
CHIR 99021  (ISO)
chloroprene  (EXP)
chlorpyrifos  (ISO)
cholesterol  (ISO)
choline  (ISO)
cisplatin  (ISO)
cobalt dichloride  (ISO)
colforsin daropate hydrochloride  (ISO)
copper atom  (EXP)
copper(0)  (EXP)
corticosterone  (EXP)
cortisol  (ISO)
crocidolite asbestos  (ISO)
curcumin  (EXP,ISO)
cyclosporin A  (EXP,ISO)
cyfluthrin  (EXP)
cyhalothrin  (EXP)
cypermethrin  (EXP)
D-glucose  (ISO)
decabromodiphenyl ether  (ISO)
dexamethasone  (ISO)
dextran sulfate  (ISO)
diarsenic trioxide  (ISO)
diazoxide  (ISO)
dioxygen  (EXP,ISO)
disodium selenite  (ISO)
diuron  (EXP)
dorsomorphin  (ISO)
doxorubicin  (ISO)
edaravone  (ISO)
entinostat  (ISO)
ethanol  (ISO)
eugenol  (EXP)
fenvalerate  (EXP)
fipronil  (EXP)
flavonoids  (EXP)
folic acid  (ISO)
formaldehyde  (ISO)
fulvestrant  (ISO)
furosemide  (EXP)
geldanamycin  (ISO)
gentamycin  (EXP)
glucose  (ISO)
glyphosate  (EXP)
haloperidol  (ISO)
hydralazine  (EXP)
hydrochlorothiazide  (EXP)
indoles  (EXP)
isoprenaline  (ISO)
L-ascorbic acid  (ISO)
L-ascorbic acid 2-phosphate  (ISO)
L-methionine  (ISO)
lanreotide  (EXP)
lipoic acid  (ISO)
lipopolysaccharide  (ISO)
losartan  (ISO)
manganese(II) chloride  (ISO)
mercury dibromide  (ISO)
methamphetamine  (EXP,ISO)
methapyrilene  (ISO)
methimazole  (EXP)
methyl methanesulfonate  (ISO)
methylmercury chloride  (ISO)
mifepristone  (EXP)
MK-2206  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
monosodium L-glutamate  (EXP)
N-acetyl-L-cysteine  (ISO)
N-methyl-N'-nitro-N-nitrosoguanidine  (EXP)
N-nitrosodiethylamine  (EXP)
nickel atom  (ISO)
nickel sulfate  (ISO)
Nilvadipine  (EXP)
NS 1619  (ISO)
orphenadrine  (EXP)
oxaliplatin  (ISO)
ozone  (EXP,ISO)
paclitaxel  (ISO)
panobinostat  (ISO)
paracetamol  (EXP,ISO)
paxilline  (ISO)
PCB138  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
phenobarbital  (EXP)
phenylephrine  (EXP)
phenylmercury acetate  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
phosgene  (EXP,ISO)
ponatinib  (ISO)
potassium dichromate  (ISO)
progesterone  (ISO)
protein kinase inhibitor  (ISO)
pyrethrins  (EXP)
rac-lactic acid  (ISO)
rebaudioside A  (ISO)
resveratrol  (ISO)
rotenone  (EXP)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
S-butyl-DL-homocysteine (S,R)-sulfoximine  (ISO)
SB 431542  (ISO)
serpentine asbestos  (ISO)
silicon dioxide  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
simvastatin  (EXP)
sodium arsenite  (ISO)
steviol  (ISO)
stevioside  (ISO)
streptozocin  (EXP,ISO)
sulfadimethoxine  (EXP)
sunitinib  (ISO)
tauroursodeoxycholic acid  (ISO)
tetrachloromethane  (EXP)
thioacetamide  (EXP,ISO)
titanium dioxide  (ISO)
toluene  (EXP)
trichloroethene  (EXP)
trichostatin A  (ISO)
troglitazone  (ISO)
tunicamycin  (ISO)
tyrphostin AG 1478  (ISO)
urethane  (ISO)
valproic acid  (EXP,ISO)
Verbenalin  (ISO)
vinclozolin  (EXP)
vincristine  (ISO)
vorinostat  (ISO)
XAV939  (ISO)
zinc atom  (EXP,ISO)
zinc protoporphyrin  (ISO)
zinc sulfate  (EXP)
zinc(0)  (EXP,ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
angiogenesis  (IEA,ISO)
blood vessel morphogenesis  (ISO,ISS)
branching involved in blood vessel morphogenesis  (ISO)
cell differentiation  (IEA)
cell migration  (ISO,ISS)
cellular response to hypoxia  (IEP)
cellular response to vascular endothelial growth factor stimulus  (ISO)
embryonic morphogenesis  (ISO,ISS)
female pregnancy  (IEP)
hyaloid vascular plexus regression  (ISO,ISS)
intracellular receptor signaling pathway  (IMP)
liver regeneration  (IEP)
monocyte chemotaxis  (IEA,ISO)
negative regulation of sprouting angiogenesis  (IDA)
negative regulation of vascular endothelial cell proliferation  (IEA,ISO)
negative regulation of vascular endothelial growth factor production  (IDA)
obsolete positive regulation of phosphatidylinositol 3-kinase activity  (ISO)
positive regulation of angiogenesis  (IEA,ISO)
positive regulation of cell migration  (IEA,IMP,ISO)
positive regulation of fibroblast proliferation  (IDA)
positive regulation of glial cell proliferation  (IMP)
positive regulation of hematopoietic progenitor cell differentiation  (ISO)
positive regulation of MAPK cascade  (IEA,IMP,ISO)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction  (ISO)
positive regulation of smooth muscle cell proliferation  (IDA)
positive regulation of vascular permeability  (ISO)
post-embryonic camera-type eye morphogenesis  (ISO)
protein phosphorylation  (IDA)
regulation of smooth muscle contraction  (IDA)
response to activity  (IEP)
response to estradiol  (IEP)
response to ethanol  (IEP)
response to hypoxia  (IDA,IEP,ISO)
sprouting angiogenesis  (ISO)
transmembrane receptor protein tyrosine kinase signaling pathway  (IBA)
vascular endothelial growth factor receptor signaling pathway  (ISO)
vascular endothelial growth factor receptor-1 signaling pathway  (IEA,ISO)
vascular endothelial growth factor signaling pathway  (IEA)

Cellular Component
actin cytoskeleton  (IEA,ISO)
endosome  (IEA)
extracellular space  (IDA,ISO)
nucleus  (ISO)
plasma membrane  (IEA,ISO,ISS)
receptor complex  (IBA,IEA,ISO)


References - curated
# Reference Title Reference Citation
1. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Ahmad S and Ahmed A, Circ Res. 2004 Oct 29;95(9):884-91. Epub 2004 Oct 7.
2. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. Arita S, etal., Int J Gynecol Cancer. 2005 Mar-Apr;15(2):329-36.
3. Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia. Bellik L, etal., Br J Pharmacol. 2005 Oct;146(4):568-75.
4. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Brennan M, etal., Eur J Clin Pharmacol. 2012 May;68(5):645-55. Epub 2011 Dec 15.
5. Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. Brown LF, etal., J Immunol. 1995 Mar 15;154(6):2801-7.
6. Expression of vascular endothelial growth factor receptors in experimental otitis media in the rat. Chae SW, etal., Acta Otolaryngol. 2003 Jun;123(5):559-63.
7. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Chen H, etal., Gynecol Oncol. 2004 Sep;94(3):630-5.
8. Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal cord contusion in rats. Choi JS, etal., J Histochem Cytochem. 2007 Aug;55(8):821-30. Epub 2007 Apr 4.
9. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Corpechot C, etal., Hepatology 2002 May;35(5):1010-21.
10. Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1. Couper LL, etal., Circ Res. 1997 Dec;81(6):932-9.
11. Compensatory growth of coronary arterioles in postinfarcted heart: regional differences in DNA synthesis and growth factor/receptor expression patterns. Dedkov EI, etal., Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1686-93. Epub 2006 May 19.
12. Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization. El Sanharawi M, etal., Gene Ther. 2013 Nov;20(11):1093-103. doi: 10.1038/gt.2013.36. Epub 2013 Jun 27.
13. Expression of vascular endothelial growth factor receptors in human prostate cancer. Ferrer FA, etal., Urology. 1999 Sep;54(3):567-72.
14. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Flisiak I, etal., Cytokine. 2010 Dec;52(3):225-9. doi: 10.1016/j.cyto.2010.09.012. Epub 2010 Oct 25.
15. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
16. Acute ethanol increases angiogenic growth factor gene expression in rat skeletal muscle. Gavin TP and Wagner PD, J Appl Physiol (1985). 2002 Mar;92(3):1176-82.
17. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. Ghanem MA, etal., J Clin Pathol. 2003 Feb;56(2):107-13.
18. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
19. Identification of four new quantitative trait loci regulating arthritis severity and one new quantitative trait locus regulating autoantibody production in rats with collagen-induced arthritis. Griffiths MM, etal., Arthritis Rheum 2000 Jun;43(6):1278-89
20. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. Hahn D, etal., J Urol. 2000 Aug;164(2):506-10.
21. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Harris AL, etal., Clin Cancer Res. 2001 Jul;7(7):1992-7.
22. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Hasumi Y, etal., Cancer Res. 2002 Apr 1;62(7):2019-23.
23. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Hazarika S, etal., Circ Res. 2007 Oct 26;101(9):948-56. Epub 2007 Sep 6.
24. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Honda M, etal., Gene Ther. 2000 Jun;7(11):978-85.
25. Identification of differentially expressed genes between osteoarthritic and normal trabecular bone from the intertrochanteric region of the proximal femur using cDNA microarray analysis. Hopwood B, etal., Bone. 2005 Apr;36(4):635-44.
26. Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. Huang H, etal., PLoS One. 2011;6(6):e21411. Epub 2011 Jun 22.
27. VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. Huang H, etal., PLoS One. 2013 Aug 20;8(8):e71808. doi: 10.1371/journal.pone.0071808. eCollection 2013.
28. Vitreous levels of proteins implicated in angiogenesis are modulated in patients with retinal or choroidal neovascularization. Huber M and Wachtlin J, Ophthalmologica. 2012;228(3):188-93. Epub 2012 Aug 4.
29. Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Ideno J, etal., Int J Mol Med. 2007 Jan;19(1):75-9.
30. Exercise training improves aging-induced downregulation of VEGF angiogenic signaling cascade in hearts. Iemitsu M, etal., Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1290-8. Epub 2006 Apr 14.
31. Differential gene expression of vascular endothelial growth factor isoforms and their receptors in the development of the rat masseter muscle. Ishii H, etal., Arch Oral Biol 2002 Jul;47(7):505-10.
32. Aqueous concentrations of VEGF and soluble VEGF receptor-1 in diabetic retinopathy patients. Javanmard SH, etal., J Res Med Sci. 2012 Dec;17(12):1124-7.
33. Differential effects of selective endothelin type a receptor antagonist on the gene expression of vascular endothelial growth factor and its receptors in streptozotocin-induced diabetic heart. Jesmin S, etal., Exp Biol Med (Maywood). 2006 Jun;231(6):902-6.
34. Time-Dependent Alterations of VEGF and Its Signaling Molecules in Acute Lung Injury in a Rat Model of Sepsis. Jesmin S, etal., Inflammation. 2011 Apr 29.
35. Expression and function of vascular endothelial growth factor receptors (Flt-1 and Flk-1) in vascular adventitial fibroblasts. Jin X, etal., J Mol Cell Cardiol. 2007 Sep;43(3):292-300. Epub 2007 Jun 18.
36. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Kaiser PK, etal., Am J Ophthalmol. 2010 Jul;150(1):33-39.e2. doi: 10.1016/j.ajo.2010.02.006.
37. Angiogenic switch and vascular stability in human Leydig cell tumours. Kilic N, etal., Angiogenesis. 1999;3(3):231-40.
38. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kim NH, etal., Kidney Int. 2005 Jan;67(1):167-77.
39. Effects of experimental type 1 diabetes and exercise training on angiogenic gene expression and capillarization in skeletal muscle. Kivela R, etal., FASEB J. 2006 Jul;20(9):1570-2.
40. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Kranenburg AR, etal., Thorax. 2005 Feb;60(2):106-13.
41. Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury. Krum JM, etal., Exp Neurol. 2008 Jul;212(1):108-17. doi: 10.1016/j.expneurol.2008.03.019. Epub 2008 Apr 3.
42. Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability. Kumai Y, etal., J Cereb Blood Flow Metab. 2007 Jun;27(6):1152-60. Epub 2006 Nov 1.
43. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. Kusmartsev S, etal., J Immunol. 2008 Jul 1;181(1):346-53.
44. High-density rat radiation hybrid maps containing over 24,000 SSLPs, genes, and ESTs provide a direct link to the rat genome sequence. Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7
45. Vascular endothelial growth factor-induced osteopontin expression mediates vascular inflammation and neointima formation via Flt-1 in adventitial fibroblasts. Li XD, etal., Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2250-8. doi: 10.1161/ATVBAHA.112.255216. Epub 2012 Jul 19.
46. Human placental expression of SLIT/ROBO signaling cues: effects of preeclampsia and hypoxia. Liao WX, etal., Biol Reprod. 2012 Apr 12;86(4):111. doi: 10.1095/biolreprod.110.088138. Print 2012 Apr.
47. Expression of hypoxia inducible factor-1alpha during liver regeneration induced by partial hepatectomy in rats. Maeno H, etal., Liver Int. 2005 Oct;25(5):1002-9.
48. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Mahasreshti PJ, etal., Clin Cancer Res. 2001 Jul;7(7):2057-66.
49. Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Manavi M, etal., Gynecol Oncol. 2007 May;105(2):418-26. Epub 2007 Feb 15.
50. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
51. The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. Mifune Y, etal., Osteoarthritis Cartilage. 2013 Jan;21(1):175-85. doi: 10.1016/j.joca.2012.09.018. Epub 2012 Oct 4.
52. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Murphy SR, etal., Hypertension. 2010 Feb;55(2):394-8. doi: 10.1161/HYPERTENSIONAHA.109.141473. Epub 2009 Dec 21.
53. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
54. Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema. Noma H, etal., Invest Ophthalmol Vis Sci. 2014 Jun 3;55(6):3878-85. doi: 10.1167/iovs.14-13961.
55. Is structural remodeling of fibrillated atria the consequence of tissue hypoxia? Ogi H, etal., Circ J. 2010 Sep;74(9):1815-21. Epub 2010 Jul 10.
56. Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization. Oh EJ, etal., Biomaterials. 2009 Oct;30(30):6026-34. doi: 10.1016/j.biomaterials.2009.07.024. Epub 2009 Jul 31.
57. VEGF receptor signalling - in control of vascular function. Olsson AK, etal., Nat Rev Mol Cell Biol. 2006 May;7(5):359-71.
58. Online Mendelian Inheritance in Man, OMIM (TM). Online Mendelian Inheritance in Man, OMIM (TM).
59. FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression. Owen LA, etal., Invest Ophthalmol Vis Sci. 2014 May 8;55(6):3543-54. doi: 10.1167/iovs.14-14047.
60. Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. Parenti A, etal., Cardiovasc Res. 2002 Jul;55(1):201-12.
61. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. Peoch M, etal., Anticancer Res 2002 Jul-Aug;22(4):2147-51.
62. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
63. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
64. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
65. GOA pipeline RGD automated data pipeline
66. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
67. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
68. Flt1 and Flk1 mediate regulation of intraocular pressure and their double heterozygosity causes the buphthalmia in mice. Sano K, etal., Biochem Biophys Res Commun. 2012 Apr 6;420(2):422-7. doi: 10.1016/j.bbrc.2012.03.011. Epub 2012 Mar 9.
69. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. Sasso FC, etal., J Am Coll Cardiol. 2005 Sep 6;46(5):827-34.
70. [Expression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinoma]. Sha D and He YJ, Ai Zheng. 2006 Feb;25(2):229-34.
71. Nine Genes Mediate the Therapeutic Effects of Iodine-131 Radiotherapy in Thyroid Carcinoma Patients. Shuwen H, etal., Dis Markers. 2020 Jun 16;2020:9369341. doi: 10.1155/2020/9369341. eCollection 2020.
72. VEGF and VEGF receptor expression after experimental brain contusion in rat. Skold MK, etal., J Neurotrauma. 2005 Mar;22(3):353-67.
73. Expression of vascular endothelial growth factor (VEGF) receptors in rat corpus luteum: regulation by oestradiol during mid-pregnancy. Sugino N, etal., Reproduction. 2001 Dec;122(6):875-81.
74. Gamma-Secretase Inhibitor, DAPT, Prevents the Development of Retinopathy of Prematurity in a Rat Model by Regulating the Delta-Like Ligand 4/Notch Homolog-1 (DLL4/Notch-1) Pathway. Sun W, etal., Med Sci Monit. 2019 Jan 17;25:492-499. doi: 10.12659/MSM.913828.
75. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. Tang JR, etal., Am J Physiol Lung Cell Mol Physiol. 2012 Jan 1;302(1):L36-46. doi: 10.1152/ajplung.00294.2011. Epub 2011 Oct 14.
76. Cerebral angiogenesis after collagenase-induced intracerebral hemorrhage in rats. Tang T, etal., Brain Res. 2007 Oct 17;1175:134-42. Epub 2007 Aug 19.
77. Tentative Sequence Identification Numbers Tentative Sequence Data IDs. TIGR Gene Index, Rat Data
78. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Toi M, etal., Int J Cancer. 2002 Mar 1;98(1):14-8.
79. Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. Tsuchiya N, etal., Tohoku J Exp Med. 2001 Oct;195(2):101-13.
80. Expression of endothelial cell angiogenesis receptors in human cerebrovascular malformations. Uranishi R, etal., Neurosurgery. 2001 Feb;48(2):359-67; discussion 367-8.
81. Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. Vihinen PP, etal., Melanoma Res. 2011 Oct;21(5):431-7. doi: 10.1097/CMR.0b013e32834941d3.
82. Zhonghua bing li xue za zhi Chinese journal of pathology Wang H, etal., Zhonghua Bing Li Xue Za Zhi. 2002 Oct;31(5):391-5.
83. [Effects of moxibustion on the expressions of hippocampal VEGF, flt-1, bFGF, and bFGF-r in vascular dementia rats]. Wang P, etal., Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 Jan;32(1):97-101.
84. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Wulfing P, etal., Br J Cancer. 2005 May 9;92(9):1720-8.
85. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Xie B, etal., Br J Cancer. 1999 Dec;81(8):1335-43.
86. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer. Yamada Y, etal., Cancer Sci. 2003 Jun;94(6):536-9.
87. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Yamane A, etal., Oncogene 1994 Sep;9(9):2683-90.
88. Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study. Yang KY, etal., Crit Care. 2011 Jan 10;15(1):R11.
89. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Yasukawa K, etal., Circulation. 2002 Feb 12;105(6):766-9.
90. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Yokoyama Y, etal., Gynecol Oncol. 2000 Jun;77(3):413-8.
91. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. Yoo SA, etal., Arthritis Rheum. 2009 Feb;60(2):345-54.
92. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Zhang X, etal., Diabetes. 2008 Apr;57(4):1026-33. doi: 10.2337/db07-0982. Epub 2008 Jan 3.
93. Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) inhibits experimental autoimmune encephalomyelitis in dark Agouti (DA) rats. Zhu CS, etal., Life Sci. 2008 Sep 12;83(11-12):404-12. doi: 10.1016/j.lfs.2008.07.009. Epub 2008 Jul 30.
94. Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer. Zhukova LG, etal., Bull Exp Biol Med. 2003 May;135(5):478-81.
Additional References at PubMed
PMID:1312256   PMID:7596436   PMID:8356051   PMID:8605350   PMID:9299537   PMID:9689083   PMID:10471394   PMID:11312102   PMID:11513746   PMID:11591653   PMID:12366396   PMID:12753865  
PMID:12796773   PMID:12923895   PMID:14633857   PMID:14982871   PMID:15001553   PMID:15601856   PMID:15838270   PMID:15919309   PMID:15952180   PMID:16109918   PMID:17311300   PMID:17402857  
PMID:17854994   PMID:17889862   PMID:18079407   PMID:18321563   PMID:18421240   PMID:18586890   PMID:18772315   PMID:18948613   PMID:19098424   PMID:19575935   PMID:19720604   PMID:19758562  
PMID:20103598   PMID:20362592   PMID:20572782   PMID:20725052   PMID:21423176   PMID:21555675   PMID:21642504   PMID:21928073   PMID:22886301   PMID:22955733   PMID:23193111   PMID:23382219  
PMID:24704473   PMID:25184477   PMID:25268360   PMID:27280428   PMID:27620880   PMID:28457321   PMID:28570669   PMID:28637396   PMID:28958753   PMID:29270751   PMID:29397206   PMID:30543046  
PMID:31583245   PMID:32039444   PMID:32972452   PMID:33444982   PMID:34169992  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2127,296,899 - 7,468,626 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl127,297,292 - 7,468,626 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx127,981,040 - 8,154,378 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0128,604,183 - 8,777,515 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0127,632,184 - 7,805,529 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0129,033,993 - 9,205,886 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl129,034,308 - 9,205,905 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01210,927,827 - 10,959,880 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4127,858,092 - 8,035,966 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
Celera129,039,046 - 9,210,055 (+)NCBICelera
RH 3.4 Map12 RGD
Cytogenetic Map12p11NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh381328,300,346 - 28,495,128 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1328,300,346 - 28,495,145 (-)EnsemblGRCh38hg38GRCh38
GRCh371328,874,483 - 29,069,265 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 361327,774,389 - 27,967,265 (-)NCBINCBI36Build 36hg18NCBI36
Build 341327,773,789 - 27,967,232NCBI
Celera139,949,266 - 10,144,048 (-)NCBICelera
Cytogenetic Map13q12.3NCBI
HuRef139,695,411 - 9,890,006 (-)NCBIHuRef
CHM1_11328,842,736 - 29,037,594 (-)NCBICHM1_1
T2T-CHM13v2.01327,522,576 - 27,717,351 (-)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm395147,498,414 - 147,663,419 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl5147,498,414 - 147,662,821 (-)EnsemblGRCm39 Ensembl
GRCm385147,561,604 - 147,726,438 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl5147,561,604 - 147,726,011 (-)EnsemblGRCm38mm10GRCm38
MGSCv375148,373,772 - 148,537,564 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv365147,872,545 - 148,036,337 (-)NCBIMGSCv36mm8
Celera5145,555,589 - 145,721,706 (-)NCBICelera
Cytogenetic Map5G3NCBI
cM Map587.01NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049554977,653,248 - 7,831,472 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049554977,653,309 - 7,831,737 (-)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan11318,995,989 - 19,190,679 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0139,584,850 - 9,779,542 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11327,926,256 - 28,120,493 (-)NCBIpanpan1.1PanPan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.12511,231,958 - 11,410,379 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl2511,231,737 - 11,407,621 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha2511,295,043 - 11,473,288 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.02511,359,770 - 11,538,425 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl2511,360,101 - 11,538,419 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.12511,255,914 - 11,434,257 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.02511,248,371 - 11,426,845 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.02511,290,416 - 11,468,726 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_024404945172,334,859 - 172,512,069 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_00493647223,440,088 - 23,617,041 (-)EnsemblSpeTri2.0
SpeTri2.0NW_00493647223,442,946 - 23,617,523 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl115,621,212 - 5,795,264 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1115,620,698 - 5,797,095 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2115,307,309 - 5,483,546 (-)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.137,412,506 - 7,608,122 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl37,412,172 - 7,607,967 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366605736,781,262 - 36,977,028 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_00462477610,043,258 - 10,219,104 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462477610,043,113 - 10,218,598 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Flt1
1066 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:147
Count of miRNA genes:114
Interacting mature miRNAs:127
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1300174Bw15Body weight QTL 152.93body mass (VT:0001259)body weight loss (CMO:0001399)1219318387Rat
2312418Kidm41Kidney mass QTL 413.70.0001kidney mass (VT:0002707)single kidney wet weight to body weight ratio (CMO:0000622)12119611090Rat
10755457Coatc14Coat color QTL 140.01759coat/hair pigmentation trait (VT:0010463)pigmented ventral coat/hair area to total ventral coat/hair area ratio (CMO:0001812)12122591684Rat
6893681Bw109Body weight QTL 1092.30.004body mass (VT:0001259)body weight (CMO:0000012)12123297788Rat
1581516Cm56Cardiac mass QTL 564.20.05heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)12129333307Rat
1598855Bp294Blood pressure QTL 2943.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)12134851688Rat
7411660Foco28Food consumption QTL 2810.90.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12142110980Rat
9590086Insglur6Insulin/glucose ratio QTL 618.970.001blood insulin amount (VT:0001560)calculated plasma insulin level (CMO:0002170)12142110980Rat
8694179Bw150Body weight QTL 1502.90.001body mass (VT:0001259)body weight gain (CMO:0000420)12142110980Rat
7411586Foco5Food consumption QTL 55.40.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12142110980Rat
7411595Foco9Food consumption QTL 940.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12142110980Rat
7411545Bw128Body weight QTL 1285.20.001body mass (VT:0001259)body weight gain (CMO:0000420)12142110980Rat
9590147Scort7Serum corticosterone level QTL 713.610.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)12142110980Rat
2303575Insul14Insulin level QTL 144blood insulin amount (VT:0001560)blood insulin level (CMO:0000349)12142450532Rat
737979Pia22Pristane induced arthritis QTL 2253.1joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)12144465750Rat
634351Apr5Acute phase response QTL 56.7blood interleukin-6 amount (VT:0008595)plasma interleukin-6 level (CMO:0001927)12144503507Rat
2302042Pia38Pristane induced arthritis QTL 383.50.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)12144503507Rat
7243862Mcs30Mammary carcinoma susceptibility QTL 308.62mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)127977298525593Rat
634350Apr4Acute phase response QTL 46orosomucoid 1 amount (VT:0010541)plasma orosomucoid 1 level (CMO:0001467)12117200546172005Rat
724526Uae3Urinary albumin excretion QTL 34.90.0001urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)12390696910373166Rat
8552918Pigfal7Plasma insulin-like growth factor 1 level QTL 7blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)12556449546669029Rat
7411547Bw129Body weight QTL 1290.001body mass (VT:0001259)body weight gain (CMO:0000420)6556449546669029Rat
7411597Foco10Food consumption QTL 100.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12556449546669029Rat
7411641Foco19Food consumption QTL 1927.70.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12556449546669029Rat
8552964Pigfal17Plasma insulin-like growth factor 1 level QTL 173.5blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)12556449546669029Rat
7411588Foco6Food consumption QTL 60.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)12556449546669029Rat
8552912Pigfal6Plasma insulin-like growth factor 1 level QTL 65blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)12556449846669029Rat
10059594Kidm46Kidney mass QTL 463.790.025kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)12610757946669029Rat
1600391Edcs2Endometrial carcinoma susceptibility QTL23.50.01uterus morphology trait (VT:0001120)percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759)12683319017870186Rat
1302792Scl21Serum cholesterol level QTL 213.80.0011blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)12719673046669029Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2127,419,974 - 7,420,119 (+)MAPPERmRatBN7.2
Rnor_6.0129,157,242 - 9,157,386NCBIRnor6.0
Rnor_5.01211,276,512 - 11,276,656UniSTSRnor5.0
RGSC_v3.4127,989,430 - 7,989,575RGDRGSC3.4
RGSC_v3.4127,989,431 - 7,989,575UniSTSRGSC3.4
RGSC_v3.1128,019,359 - 8,019,503RGD
Celera129,161,501 - 9,161,645UniSTS
RH 3.4 Map1278.6UniSTS
RH 3.4 Map1278.6RGD
RH 2.0 Map1265.2RGD
Cytogenetic Map12p11UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2127,373,601 - 7,373,808 (+)MAPPERmRatBN7.2
Rnor_6.0129,111,054 - 9,111,260NCBIRnor6.0
Rnor_5.01211,230,613 - 11,230,819UniSTSRnor5.0
RGSC_v3.4127,943,881 - 7,944,087UniSTSRGSC3.4
Celera129,115,304 - 9,115,510UniSTS
RH 3.4 Map1274.7UniSTS
Cytogenetic Map12p11UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2127,388,774 - 7,388,932 (+)MAPPERmRatBN7.2
Rnor_6.0129,126,047 - 9,126,204NCBIRnor6.0
Rnor_5.01211,245,471 - 11,245,628UniSTSRnor5.0
RGSC_v3.4127,958,213 - 7,958,370UniSTSRGSC3.4
Celera129,130,303 - 9,130,460UniSTS
RH 3.4 Map1283.6UniSTS
Cytogenetic Map12p11UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2127,428,613 - 7,428,780 (+)MAPPERmRatBN7.2
Rnor_6.0129,165,880 - 9,166,046NCBIRnor6.0
Rnor_5.01211,285,150 - 11,285,316UniSTSRnor5.0
RGSC_v3.4127,998,069 - 7,998,235UniSTSRGSC3.4
Celera129,170,109 - 9,170,275UniSTS
RH 3.4 Map1284.6UniSTS
Cytogenetic Map12p11UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2127,466,375 - 7,466,463 (+)MAPPERmRatBN7.2
Rnor_6.0129,203,636 - 9,203,723NCBIRnor6.0
Rnor_5.01211,322,790 - 11,322,877UniSTSRnor5.0
RGSC_v3.4128,035,831 - 8,035,918UniSTSRGSC3.4
Celera129,207,805 - 9,207,892UniSTS
RH 3.4 Map1281.9UniSTS
Cytogenetic Map12p11UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2127,387,710 - 7,387,886 (+)MAPPERmRatBN7.2
Rnor_6.0129,124,983 - 9,125,158NCBIRnor6.0
Rnor_5.01211,244,407 - 11,244,582UniSTSRnor5.0
RGSC_v3.4127,957,149 - 7,957,324UniSTSRGSC3.4
Celera129,129,239 - 9,129,414UniSTS
RH 3.4 Map1287.01UniSTS
Cytogenetic Map12p11UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2127,446,427 - 7,448,109 (+)MAPPERmRatBN7.2
Rnor_6.0129,183,689 - 9,185,370NCBIRnor6.0
Rnor_5.01211,302,959 - 11,304,640UniSTSRnor5.0
RGSC_v3.4128,015,880 - 8,017,561UniSTSRGSC3.4
Celera129,187,906 - 9,189,587UniSTS
Cytogenetic Map12p11UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 37 12 2 13 2 6 7 24 31 10 11 6
Low 3 6 45 39 6 39 2 4 50 4 31 2
Below cutoff


RefSeq Acc Id: ENSRNOT00000001248   ⟹   ENSRNOP00000001248
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl127,297,292 - 7,468,626 (+)Ensembl
Rnor_6.0 Ensembl129,034,308 - 9,205,905 (+)Ensembl
RefSeq Acc Id: NM_001309381   ⟹   NP_001296310
RefSeq Status: VALIDATED
Rat AssemblyChrPosition (strand)Source
mRatBN7.2127,297,292 - 7,391,757 (+)NCBI
Rnor_6.0129,034,409 - 9,129,029 (+)NCBI
Celera129,039,046 - 9,133,285 (+)NCBI
RefSeq Acc Id: NM_019306   ⟹   NP_062179
RefSeq Status: VALIDATED
Rat AssemblyChrPosition (strand)Source
mRatBN7.2127,297,292 - 7,468,626 (+)NCBI
Rnor_6.0129,034,409 - 9,205,886 (+)NCBI
Rnor_5.01210,927,827 - 10,959,880 (-)NCBI
RGSC_v3.4127,858,092 - 8,035,966 (+)RGD
Celera129,039,046 - 9,210,055 (+)NCBI
RefSeq Acc Id: XM_008768998   ⟹   XP_008767220
Rat AssemblyChrPosition (strand)Source
mRatBN7.2127,296,899 - 7,393,673 (+)NCBI
Rnor_6.0129,033,993 - 9,130,272 (+)NCBI
RefSeq Acc Id: NP_062179   ⟸   NM_019306
- Peptide Label: isoform 1 precursor
- UniProtKB: P53767 (UniProtKB/Swiss-Prot),   G3V633 (UniProtKB/TrEMBL),   A6K197 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_008767220   ⟸   XM_008768998
- Peptide Label: isoform X1
- UniProtKB: Q9JJ08 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: NP_001296310   ⟸   NM_001309381
- Peptide Label: isoform 2 precursor
- UniProtKB: A6K198 (UniProtKB/TrEMBL),   Q9JJ08 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000001248   ⟸   ENSRNOT00000001248
Protein Domains
Ig-like   Ig-like C2-type   Protein kinase

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P53767-F1-model_v2 AlphaFold P53767 1-1336 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2621 AgrOrtholog
BioCyc Gene G2FUF-20125 BioCyc
Ensembl Genes ENSRNOG00000000940 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000001248 ENTREZGENE
  ENSRNOP00000001248.2 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000001248 ENTREZGENE
  ENSRNOT00000001248.4 UniProtKB/TrEMBL
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Transferase(Phosphotransferase) domain 1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Ig-like_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig-like_fold UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_I-set UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_sub UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_sub2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kinase-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Prot_kinase_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Protein_kinase_ATP_BS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ser-Thr/Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_AS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_rcpt_3_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  VEGFR-2_TMD UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  VEGFR1_rcpt UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SI:ZFOS-1069F5.1 UniProtKB/TrEMBL
Pfam I-set UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_3 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Pkinase_Tyr UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  VEGFR-2_TMD UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Flt1 PhenoGen
PIRSF TyrPK_CSF1-R UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  VEGFRECEPTR1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART IGc2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SM00409 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TyrKc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF48726 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF56112 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
TIGR TC208889
  VGFR1_RAT UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2020-01-03 Flt1  Fms related receptor tyrosine kinase 1  Flt1  FMS-related tyrosine kinase 1  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2015-06-08 Flt1  FMS-related tyrosine kinase 1  LOC100911280  vascular endothelial growth factor receptor 1-like  Data Merged 737654 APPROVED
2012-07-05 LOC100911280  vascular endothelial growth factor receptor 1-like      Symbol and Name status set to provisional 70820 PROVISIONAL
2011-04-29 Flt1  FMS-related tyrosine kinase 1  Flt1  fms-related tyrosine kinase 1  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-11-14 Flt1  fms-related tyrosine kinase 1  Flt1  FMS-like tyrosine kinase 1  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2002-11-06 Flt1  FMS-like tyrosine kinase 1    Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)  Name updated 625702 APPROVED
2002-06-10 Flt1  Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_expression expressed in liver sinusoidal endothelial cells 728597